Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)

INTRODUCTION: Pulmonary arterial hypertension (PAH) is associated with poor prognosis despite significant recent advances in its treatment. An intravenous formulation of epoprostenol sodium containing glycine and mannitol (epoprostenol GM; GlaxoSmithKline, London, UK) is widely used to treat PAH. A...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Tamura, Yuichi, Ono, Tomohiko, Fukuda, Keiichi, Satoh, Toru, Sasayama, Shigetake
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2013
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3680653/
https://ncbi.nlm.nih.gov/pubmed/23653230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-013-0029-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items